Early CMR in Acute MI (Early AMI-CMR)

May 19, 2026 updated by: The Affiliated Hospital of Xuzhou Medical University

Exploring the Application and Value of Cardiac Magnetic Resonance in Acute Myocardial Infarction

The goal of this observational study is to evaluate the clinical utility of cardiac magnetic resonance (CMR) in patients with acute myocardial infarction (AMI). This is a retrospective and prospective cohort study that has already enrolled a number of patients and will continue to enroll additional patients on a rolling basis.

The main question it aims to answer is:

How does CMR, performed acute phase, contribute to risk stratification, prognostic assessment, and long-term clinical management in patients with AMI?

Participants who have had an AMI will undergo CMR within one week of symptom onset. After discharge, they will be regularly followed up at 1, 3, 6, 9, and 12 months, and then every 6 months thereafter. Clinical outcomes will be collected during each follow-up visit.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This is an ambispective observational cohort study. The study will include patients who have already undergone CMR examination and meet the eligibility criteria, as well as consecutively enrolled patients who will undergo CMR during the prospective study period.

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Jiangsu
      • Xuzhou, Jiangsu, China, 221000
        • The Affiliated Hospital of Xuzhou Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with AMI and who underwent CMR within the acute phase of symptom onset.

Description

Inclusion Criteria:

  • Patients aged 18 years or older.
  • Patients diagnosed with acute myocardial infarction.
  • Patients who complete cardiovascular magnetic resonance imaging during the acute phase after symptom onset.
  • Patients with available clinical, CMR, and follow-up data.

Exclusion Criteria:

  • History of previous myocardial infarction.
  • Severe renal insufficiency, defined as estimated glomerular filtration rate <30 mL/min/1.73 m².
  • Presence of malignant tumors.
  • Poor CMR image quality unsuitable for analysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
AMI
Other: Cardiac magnetic resonance imaging
Cardiovascular magnetic resonance imaging will be used to assess cardiac structure, function, myocardial injury, infarct size, late gadolinium enhancement, microvascular obstruction, and other CMR-derived parameters. This is an observational cohort study, and no diagnostic test or treatment will be assigned by the investigators. CMR examinations have been or will be performed as part of routine clinical evaluation according to clinical indications.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Major Adverse Cardiovascular Events (MACE)
Time Frame: through study completion, an average of 5 years
A composite of cardiovascular death, non-fatal myocardial infarction, unplanned coronary revascularization, and hospitalization for heart failure. Assessed from the date of index hospitalization through the end of follow-up.
through study completion, an average of 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiac Magnetic Resonance (CMR) Imaging Parameters
Time Frame: Baseline
Presence of microvascular obstruction assessed by late gadolinium enhancement cardiovascular magnetic resonance imaging.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 31, 2018

Primary Completion (Estimated)

March 23, 2046

Study Completion (Estimated)

March 23, 2046

Study Registration Dates

First Submitted

March 22, 2026

First Submitted That Met QC Criteria

May 19, 2026

First Posted (Actual)

May 22, 2026

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • XYFY2026-KL154-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Myocardial Infarction (AMI)

Clinical Trials on Cardiac magnetic resonance imaging

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe